Slides
Page 1
Investor Presentation Q2 2026. 1
Page 2
Safe Harbor Statement 2 • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. You should understand that, even though our forward-looking statements are based on assumptions we believe are reasonable when made, they are still subject to uncertainties that could cause actual results to differ materially from those in the forward-looking statements. • Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. • Forward-looking statements made herein are summaries of previous public disclosures, do not represent revised guidance, and we do not undertake to revise or update them from the date or dates of previous disclosure. • In the case of any presentation delivered during the company’s prescribed black-out periods, there will be no discussion or questions addressed regarding the current quarter’s expected performance.
Page 3
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 3 Financial Performance & Capital Allocation04
Page 4
4 Q2 Key Takeaways 1. Record quarterly sales and earnings highlight the continued strength of our business 2. All three business segments delivered strong sales and profit growth, showcasing the quality of our portfolio 3. Strategic growth initiatives are progressing well and supporting a favorable growth outlook 4. Renewed our revolving credit facility with expanded capacity to fund future growth Balchem continues to deliver strong growth +11.2% Q2 Sales vs. PY +12.6% Q2 Adj. EBITDA vs. PY 97% Q2 TTM* FCF conversion * TTM: Trailing Twelve Months
Page 5
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 5 Financial Performance & Capital Allocation04
Page 6
BCPC Balchem Corporation At a Glance 1967 Founded in 6 2025 Adjusted EBITDA 2025 Adjusted EBITDA margin 26.5% $275 Million Approximate number of employees 1,400 $1.0 Billion 2025 Sales NASDAQ
Page 7
7 Three Business Segments – 2025 Revenue Animal Nutrition & Health Specialty ProductsHuman Nutrition & Health Provides a range of branded specialty minerals, nutrients, and vitamins as well as microencapsulation technologies and food ingredient formulation systems for the supplement, beverage, cereal, meat, and bakery markets. Supplies science-based animal feed nutritional ingredients and proprietary microencapsulation technologies for production animal productivity and ruminant and companion animal wellness. Provides critical sterilization technologies to the medical device and food industries and supplies specialized chelated minerals to the micronutrient agricultural market. 64% 22% 14% Human Nutrition & Health Animal Nutrition & Health Specialty Products
Page 8
Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place. 8 Corporate Headquarters: Montvale, NJ 22 Manufacturing Sites 8 Technology Centers 8 Regional Offices
Page 9
Executive Leadership Ted Harris Chairman, President, and CEO • Joined Balchem in May 2015 • Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years • Independent director on the Board of Directors of Pentair plc • MBA from Harvard University and bachelor’s degree from Lehigh University in chemical engineering Martin Bengtsson CFO • Joined Balchem in February 2019 • Prior to Balchem had a 15-year career at Honeywell and most recently was CFO for the $11B Performance Materials & Technologies segment • Bachelor’s degree from Northwestern University in economics and began career as Senior Auditor for Deloitte 9
Page 10
Value to our customers • High efficacy nutrients essential for life • Enhanced animal health and feed productivity • Functional ingredient systems formulations and applications expertise • Crop protection and yield improvement • Complete supply chain capabilities and assurance Value to society • Increased health and well-being of humans and animals • Enhanced food chain productivity to give a growing population sustainable access to food Technologies 10 Value Proposition
Page 11
Human Nutrition & Health Animal Nutrition & Health Specialty Products Segment Markets Served Solutions Human Nutrition & Health • Nutritional Supplements • Sport & Active Nutrition • Infant and Toddler Formula • Healthy Snacking • Functional Beverages • Food and Beverage • Microencapsulation • Choline and Vitamin K2 • Chelated Minerals • Functional Solutions and Systems Animal Nutrition & Health • Dairy • Poultry and Swine • Companion Animal • Aquaculture • Microencapsulation • Choline • Chelated Minerals • Amino Acids and Other Nutrients Specialty Products • Medical Device Sterilization • Nut and Spice Fumigation • Plant Nutrition • Choline • Chelated Minerals • Performance Gases re-packaging and supply chain capabilities 64% 22% 14% Segment Overview 11 Leveraging Solutions Across Segments 2025 Revenue by Segment
Page 12
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 12 Financial Performance & Capital Allocation04
Page 13
Our Vision is clear – to make the world a healthier place. Our Mission is focused – to build a global nutrition and health company delivering trusted, innovative and science-based solutions to our customers. Our Core Values Always Doing the and Acting Small Collaborating and Growing Playing to Staying on the 13
Page 14
How Do We Make the World a Healthier Place? Provide food, beverage, and dietary supplement ingredients that support cognitive, emotional, and physical well- being across generations Improve nutrient bioavailability for animals, reducing feed inputs and land required to produce high-quality animal protein Support prenatal, infant, and toddler health with targeted nutritional ingredients Help farmers grow crops that are hardier when faced with stressors like disease and pests Provide nutritious foods for companion animals Improve nutrient bioavailability to reduce animal waste excreted into the environment Power the day with plant & animal proteins, healthy fats, minerals, nutrients, and specialty nutraceuticals Create higher yields and higher quality crops with fewer inputs Decrease food waste from farm to table via natural technologies Provide products to medical device sterilizers 14
Page 15
Strategic Focus Strengthening Positions in Attractive, Growing Markets Building scale, adding adjacent capabilities, expanding market and geographic reach, broadening our portfolio of solutions, investing in new science, enabling market awareness Driving Organic Growth Creating new demand through innovation, market penetration, new product launches, geographic expansion, and expanding addressable markets Strategic M&A Augmenting organic growth and accelerating strategic initiatives 01 02 03 Excellence in Execution Maintaining a strong margin profile, efficient cash flow conversion, and a solid balance sheet 04 15
Page 16
Specialty Nutrients Science-backed portfolio of branded ingredients, such as VitaCholine®, K2Vital , Albion® Minerals, OptiMSM® Micro- encapsulation Food safety and preservation M&A Accelerate our strategic priorities, adding adjacent products / technologies, and geographic reach Nutrient Delivery Systems For The Dairy Market Rumen-bypass precision release technology for efficient nutrient delivery Functional Solutions Delivering high protein, high fiber or clean label functional solutions for fast- growing “Better for You” food and beverage categories Growth Platforms Multiple Platforms to Drive Growth Above Market Growth 16 New Product Development Next generation, breakthrough, and new to the world innovations Specialty Products Metalosate® plant micro- nutrient market penetration Geographic Expansion Expansion into under- served geographies
Page 17
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 17 Financial Performance & Capital Allocation04
Page 18
255.5 284.0 2Q25 2Q26 69.2 77.9 2Q25 2Q26 41.6 48.1 2Q25 2Q26 1.27 1.49 2Q25 2Q26 Q2 2026 Financial Summary Record sales and profit in the second quarter 18 Sales $M 11.2% Adj. EBITDA $M 12.6% Adj. Net Earnings $M 15.7% Adj. EPS $/share 17.3% Improved profitability and lower interest expense Driven by sales growth across the portfolio Earnings growth further supported by a modest reduction in diluted outstanding shares Strong growth in all three segments: HNH, ANH, and SP
Page 19
506.0 554.7 YTD25 YTD26 135.5 152.2 YTD25 YTD26 81.6 91.1 YTD25 YTD26 2.49 2.83 YTD25 YTD26 YTD 2026 Financial Summary Strong sales and profit growth 19 Sales $M 9.6% Adj. EBITDA $M 12.3% Adj. Net Earnings $M 11.7% Adj. EPS $/share 13.7% Improved profitability and lower interest expense, partially offset by a higher adjusted tax rate Driven by sales growth across the portfolio Earnings growth further supported by a modest reduction in diluted outstanding shares Strong growth in all three segments: HNH, ANH, and SP
Page 20
Historical Financials 174 190 216 231 250 275 152 2020 2021 2022 2023 2024 2025 YTD 2026 704 799 942 922 954 1,037 555 2020 2021 2022 2023 2024 2025 YTD 2026 108 117 131 130 143 168 91 2020 2021 2022 2023 2024 2025 YTD 2026 3.32 3.57 4.03 4.00 4.37 5.15 2.83 2020 2021 2022 2023 2024 2025 YTD 2026 +8.1% CAGR +9.3% CAGR Sales $M Adj. EBITDA $M Adj. Net Earnings $M Adj. EPS $/share 20 Consistent performance over the years +9.2% CAGR +9.6% CAGR
Page 21
Capital Allocation Strategy Capital Allocation Priorities • Support organic growth opportunities • Augment growth with targeted M&A • Diligent debt service • Continue to pay and grow dividend • Stock buy-backs for anti-dilution M&A • Eight acquisitions since 2016 to augment organic growth • Focus on nutrition and health • Adding geographic reach and adjacent products / technologies Annual Cash Flow and Net Debt Leverage Ratio 108 111 119 124 150 161 139 184 182 217 220 1.6 1.2 0.6 1.1 0.5 0.0 1.7 1.1 0.6 0.3 0.3 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Q2 2026 TTM* Cash Flow From Operations Net Debt divided by TTM* Adj. EBITDA 21 * TTM: Trailing Twelve Months
Page 22
Free Cash Flow Conversion 105% 102% 102% 93% 109% 107% 69% 116% 103% 103% 97% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Q2 2026 TTM* Free Cash Flow as % of Non-GAAP Net Earnings 100% 22 Translating profits into cash * TTM: Trailing Twelve Months
Page 23
Recent Acquisitions Augmenting Organic Growth with Targeted Acquisitions Close to Core Albion Minerals • Adjacent product offering in high growth market • Chelated Magnesium, Iron, Calcium, Zinc, etc. 2016 Chemogas • Geographic expansion of market leadership to Europe • Performance gas solutions Zumbro River Brand • Consolidation and portfolio extension • High protein extrusion and agglomeration 2019 Kappa Bioscience • Portfolio extension in high growth specialty vitamin market • Vitamin K2 and MK -7 Bergstrom Nutrition • Portfolio extension in high growth specialty mineral market • Specialty sulfur for supplements 2022 Bioscreen • Geographic expansion and processing technology • Microencapsulation and fermentation 2018 IFP • Market consolidation and processing technology • Microencapsulation and agglomeration 2017 23 GFR Ingredients • Geographic expansion and processing technology • Spray Drying assets for Minerals portfolio 2024
Page 24
Dividends Consistent dividend policy 0.34 0.38 0.42 0.47 0.52 0.58 0.64 0.71 0.79 0.87 0.96 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 ($/share) +10.9% CAGR Annual double-digit dividend growth for the last decade Consistency in execution 24
Page 25
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 25 Financial Performance & Capital Allocation04
Page 26
8th sustainability report released in April 2026 5th anniversary of UN Global Compact commitment is marked Enhanced transparency reported to EcoVadis® and CDP Scope 3 GHG emissions successfully measured and reported Surpassed our 2030 GHG emissions reduction goal, by reducing Scope 1 and 2 emissions by 31% in 2025, from our 2020 baseline Reduced our water withdrawal in 2025 by 16% from our 2020 baseline and remain on track to meet 2030 goal ~75% of our 2025 product revenue aligns with at least one UN SDG (SDGs 2, 3, and 12) Recent Sustainability Progress Making the world a healthier place 26 Learn more about our sustainability programs: Third-party trademarks may be referenced for informational purposes only; no affiliation or endorsement is intended
Page 27
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 27 Financial Performance & Capital Allocation04
Page 28
Leading positions in attractive markets Creating new demand through innovation Strong financial performance, delivering healthy margins and cash flows available for reinvestment Proven track record and well positioned for the future Balchem Summary A global nutrition and health company delivering trusted, innovative and science-based solutions to our customers 28
Page 29
Agenda Q2 2026 Key Takeaways Balchem Overview Vision and Strategic Focus Sustainability Wrap Up Appendix GAAP to Non-GAAP reconciliations 01 02 03 05 06 07 29 Financial Performance & Capital Allocation04
Page 30
Non-GAAP Financial Information In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this presentation contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this presentation include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the following reconciliation tables and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures. 30
Page 31
Non-GAAP Financial Information 31
Page 32
Non-GAAP Financial Information 32
Page 33
Non-GAAP Financial Information 33
Page 34
Non-GAAP Financial Information 34 (1) Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, and finance leases. We record expense relating to the amortization of these intangibles and finance leases in our GAAP financial statements. Amortization expenses for our intangible assets and finance leases are inconsistent in amount and are significantly impacted by the timing and valuation of acquisitions. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. (2) Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (3) Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. (4) Restructuring costs: Restructuring costs related to a reorganization of the business are recorded in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. (5) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. (6) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and six months ended June 30, 2026 and 2025, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.
Page 35
35